null

Belgium 19-3-26 Country Members Physical french

Vendor Detox: La consolidation vaut-elle le risque ?

Moins de Partenaires : La consolidation vaut-elle le risque ? Le problème est la prolifération des fournisseurs : trop d'outils causant de la complexité, une taxe d'intégration paralysante et de la redondance. La Taxe d'Intégration est le coût caché (en temps, en échecs et en ressources) d'essayer de faire fonctionner ensemble des systèmes disparates. Cet échange se concentre sur des stratégies éprouvées pour simplifier de manière agressive le parc technologique, consolider les fournisseurs et élever certains fournisseurs clés au rang de partenaires stratégiques.

Belgium 24-3-26 Invitation Only Physical english

Killing Zombie Projects: Knowing when to stop, restart, or quietly let go

Every organisation has them, projects that keep running long after their purpose has faded. No one remembers who asked for them, but shutting them down feels riskier than keeping them alive. And eventually, people stay assigned, budgets stay allocated, and energy drains into work that no longer matters. Inertia at its finest. Ending a project is rarely a technical decision. It’s emotional, political, and often tied to past promises or personal reputation. The longer something runs, the harder it becomes to admit it’s time to stop. Yet clearing that backlog of half-dead initiatives is often the only way to make room for new ones. So how do you decide when to pull the plug? What signals show that value is gone, and who gets to say so? How can governance encourage honest calls without punishing those who make them? Let’s discuss how to end gracefully, refocus teams, and turn closure into confidence rather than blame. Bullet in the head? Is that how you kill a zombie, or was it a silver bullet in the heart? A closed conversation on how to make progress by learning to stop.

Belgium 26-3-26 Invitation Only Virtual english

Measuring Value in AI Initiatives: Defining ROI, accountability, and measurable outcomes in complex environments

AI projects continue to multiply, but proving their value remains difficult. Most organisations can track activity, not impact. Dashboards count pilots and models, yet few translate to measurable business outcomes. The result is familiar: success stories without clarity on what they actually delivered. The real issue is measurement. Traditional ROI metrics fail when AI changes decisions more than results. Financial indicators miss the operational gains, while qualitative benefits often sound too vague to defend. Without clear evidence, budgets come under scrutiny and confidence erodes. This session focuses on how to connect AI work with business outcomes through structured metrics, governance, and accountability. We’ll explore how value tracking evolves from experimentation to scale, which indicators earn trust at board level, and where measurement stops being meaningful. A closed exchange for comparing methods, tools, and lessons learned in defining, proving, and sustaining AI impact.

March 24, 2026 Squad Session Invitation Only Physical english

Killing Zombie Projects: Knowing when to stop, restart, or quietly let go

March 26, 2026 Squad Session Invitation Only Physical english

Measuring Value in AI Initiatives: Defining ROI, accountability, and measurable outcomes in complex environments

March 31, 2026 Squad Session Invitation Only Physical english

Composability in Practice: Building modular systems that stay coherent as they grow

Composability sounds elegant in theory: small, independent parts that come together to form something greater, but in practice, it’s messy. What happens when modules overlap, APIs evolve differently across domains, and governance struggles to keep pace? What was meant to simplify architecture sometimes ends up multiplying it.

Please Log In with your CIONET account first

Exscientia Uses Generative AI to Reimagine Drug Discovery

Exscientia uses generative artificial intelligence (AI) throughout the design-make-test-learn (DMTL) cycle to discover new therapies for patients quickly and relatively inexpensively.

“Using AWS, we reduce bottlenecks and accelerate the pipeline.”

David Hallett
Interim CEO and Chief Scientific Officer, Exscientia

Exscientia uses generative artificial intelligence (AI) throughout the design-make-test-learn (DMTL) cycle to discover new therapies for patients quickly and relatively inexpensively. Conventional drug discovery methods can take up to 15 years and cost over 2 billion dollars, with an average failure rate of 90–96 percent because scientists hunt for specific drug candidates among 10⁶⁰ bioavailable small molecules.

Built on Amazon Web Services (AWS), Exscientia’s innovative DMTL solution incorporates in silico design—using generative AI algorithms to design compounds in the cloud—and automated robots that make drug candidates in a lab. “We use generative AI to solve for efficiency and effectiveness,” says David Hallett, Exscientia’s interim CEO and chief scientific officer. “By predicting the molecular features of a safe and effective drug in silico, we minimize the number of costly experiments. Our platform, built in collaboration with the AWS team, is optimized for speed. We can repeat many DMTL learning loops, improving our drug candidates with every iteration.”

Using Generative AI for More Efficient Drug Discovery at Reduced Cost

Working backward from patient needs, Exscientia defines precise target product profiles (TPPs) that specify the complex combination of properties required by a well-tolerated and effective medicine. AI engineers design algorithms that generate panels of potential drug candidates to meet the TPPs. Active learning algorithms help expert designers to select a short list of drug candidates to synthesize in the lab, because they either move the TPPs forward or refine the models for future DMTL cycles.

Exscientia’s algorithms are trained on publicly available pharmacology data and proprietary in-house data generated from patient tissue samples, genomics, single-cell transcriptomics, and medical literature. By encoding data throughout the process and analyzing experimental results and previous design cycles, Exscientia can optimize upcoming design cycles and promote compound designs that are physically synthesizable. Using this synthesis-aware, iterative approach built on AWS, Exscientia makes 10 times fewer compounds than the industry average. “The idea is to iron out chemical liabilities to make safer and more effective drug candidates before we ever test them in patients,” says Hallett.

Exscientia has accelerated drug design by up to 70 percent while decreasing capital cost by 80 percent, compared with industry benchmarks. Using generative AI with other tools, Exscientia not only developed better drug candidates faster but also identified the right drug combinations to trial with patients in the clinic.

Cutting Time and Costs Using Automated Robotics to Make Better Medicines

Exscientia has incorporated cutting-edge chemistry synthesis and biology assay lab equipment with automation robots to avoid manual handling of lab equipment. Thus, its lab—orchestrated by AWS microservices—can operate 24/7 with minimal human supervision, “When our designs are ready, we can push a button, and within a few days, the robots are making the drug,” says Hallett. Maintaining extremely high levels of security and comprehensive disaster recovery, Exscientia will use this automated robotic capability to reduce the make and test timelines resulting from traditional offshore research contracts used across the industry.

As the company closes the loop with its robotic automation lab, it expects further productivity improvements. Data generated in the lab improves algorithmic predictions and speeds up DMTL cycles.

Introducing AI-Designed Molecules into Clinical Trials

Six molecules that Exscientia designed using AI have entered clinical trials. “Using AWS, we reduce bottlenecks and accelerate the pipeline,” says Hallett. “By switching on this highly integrated and automated DMTL loop, we can make drug candidates faster and more cost-effective.”

Technologies

Amazon Bedrock

Partners

CIONET Business Circles

Healthcare Circle

Digital Transformation is redefining the future of health care and health delivery. All stakeholders are convinced that these innovations will create value for patients, healthcare practitioners, hospitals, and governments along the patient pathway. The benefits are starting from prevention and awareness to diagnosis, treatment, short- and long-term follow-up, and ultimately survival. But how do you make sure that your working towards an architecturally sound, secure and interoperable health IT ecosystem for your hospital and avoid implementing a hodgepodge of spot solutions? How does your IT department work together with the other stakeholders, such as the doctors and other healthcare practitioners, Life Sciences companies, Tech companies, regulators and your internal governance and administrative bodies?

Telenet Business Leadership Circle

The Telenet Business Leadership Circle powered by CIONET, offers a platform where IT executives and thought leaders can meet to inspire each other and share best practices. We want to be a facilitator who helps you optimise the performance of your IT function and your business by embracing the endless opportunities that digital change brings.

Les Rencontres

Découvrez la dynamique du leadership numérique aux Rencontres de CIONET, le programme francophone exclusif de CIONET pour les leaders numériques en Belgique, rendu possible grâce au soutien et à l'engagement de nos partenaires de programme : Deloitte, Denodo et Red Hat. Rejoignez trois événements inspirants par an à Liège, Namur et en Brabant Wallon, où des CIOs et des experts numériques francophones de premier plan partagent leurs perspectives et expériences sur des thèmes d'affaires et de IT actuels. Laissez-vous inspirer et apprenez des meilleurs du secteur lors de sessions captivantes conçues spécialement pour soutenir et enrichir votre rôle en tant que CIO pair. Ne manquez pas cette opportunité de faire partie d'un réseau exceptionnel d'innovateurs numériques !

Female Leadership Circle

CIONET is committed to highlighting and celebrating female role models in IT, Tech & Digital, creating a leadership programme that empowers and elevates women within the tech industry. This initiative is dedicated to showcasing the achievements and successes of leading women, fostering an environment where female role models are recognised, and their contributions can ignite progress and inspire the next generation of women in IT. Our mission is to shine the spotlight a little brighter on female role models in IT, Tech & Digital, and to empower each other through this inner network community.